Mobocetinib is an oral EGFR tyrosine kinase inhibitor specifically targeting EGFR exon 20 insertion mutations, used to treat non-small cell lung cancer (NSCLC) patients.

1. Main treatment for diseases

(1) Non small cell lung cancer: suitable for treating locally advanced or metastatic adult patients with EGFR exon 20 insertion mutations.

2 Applicable Population

(1) EGFR exon 20 insertion mutation patients: NSCLC patients confirmed by FDA approved testing methods to have EGFR exon 20 insertion mutations.

(2) Patients with previous treatment failures: suitable for patients with disease progression during or after previous platinum based chemotherapy.

3 Characteristics of Function

(1) Targeted therapy: Specific inhibition of EGFR exon 20 insertion mutation fills the gap in targeted therapy for this mutation type.

(2) Oral administration: convenient for patients to use and improves treatment compliance.

(3) Breakthrough therapy: Targeting patients with EGFR exon 20 insertion mutations who have poor efficacy with traditional EGFR-TKI.